869 related articles for article (PubMed ID: 28577840)
1. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Foley D; Sievert H; Mazzone P; De Potter T; Vireca E; Stein K; Bergmann MW;
Heart Rhythm; 2017 Sep; 14(9):1302-1308. PubMed ID: 28577840
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.
Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Mazzone P; Foley D; Grygier M; Sievert H; De Potter T; Vireca E; Stein K; Bergmann MW;
Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006841. PubMed ID: 30939908
[TBL] [Abstract][Full Text] [Related]
3. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).
Reddy VY; Möbius-Winkler S; Miller MA; Neuzil P; Schuler G; Wiebe J; Sick P; Sievert H
J Am Coll Cardiol; 2013 Jun; 61(25):2551-6. PubMed ID: 23583249
[TBL] [Abstract][Full Text] [Related]
4. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
[TBL] [Abstract][Full Text] [Related]
5. Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure.
Saw J; Fahmy P; Azzalini L; Marquis JF; Hibbert B; Morillo C; Carrizo A; Ibrahim R
J Cardiovasc Electrophysiol; 2017 Apr; 28(4):396-401. PubMed ID: 28128883
[TBL] [Abstract][Full Text] [Related]
6. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
[TBL] [Abstract][Full Text] [Related]
8. Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation.
Fauchier L; Cinaud A; Brigadeau F; Lepillier A; Pierre B; Abbey S; Fatemi M; Franceschi F; Guedeney P; Jacon P; Paziaud O; Venier S; Deharo JC; Gras D; Klug D; Mansourati J; Montalescot G; Piot O; Defaye P
J Am Coll Cardiol; 2018 Apr; 71(14):1528-1536. PubMed ID: 29622159
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries.
Holmes DR; Reddy VY; Gordon NT; Delurgio D; Doshi SK; Desai AJ; Stone JE; Kar S
J Am Coll Cardiol; 2019 Dec; 74(23):2878-2889. PubMed ID: 31806131
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry.
Bergmann MW; Betts TR; Sievert H; Schmidt B; Pokushalov E; Kische S; Schmitz T; Meincke F; Stein KM; Boersma LVA; Ince H
EuroIntervention; 2017 Sep; 13(7):877-884. PubMed ID: 28606886
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of the WATCHMAN Device in LAA Occlusion in Patients with Non-Valvular Atrial Fibrillation Contraindicated to Oral Anticoagulation: A Focused Review.
Majule DN; Jing C; Rutahoile WM; Shonyela FS
Ann Thorac Cardiovasc Surg; 2018 Dec; 24(6):271-278. PubMed ID: 29962388
[TBL] [Abstract][Full Text] [Related]
12. The clinical impact of incomplete left atrial appendage closure with the Watchman Device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy.
Viles-Gonzalez JF; Kar S; Douglas P; Dukkipati S; Feldman T; Horton R; Holmes D; Reddy VY
J Am Coll Cardiol; 2012 Mar; 59(10):923-9. PubMed ID: 22381428
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR; Kar S; Price MJ; Whisenant B; Sievert H; Doshi SK; Huber K; Reddy VY
J Am Coll Cardiol; 2014 Jul; 64(1):1-12. PubMed ID: 24998121
[TBL] [Abstract][Full Text] [Related]
14. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes.
Dukkipati SR; Kar S; Holmes DR; Doshi SK; Swarup V; Gibson DN; Maini B; Gordon NT; Main ML; Reddy VY
Circulation; 2018 Aug; 138(9):874-885. PubMed ID: 29752398
[TBL] [Abstract][Full Text] [Related]
15. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study.
Bergmann MW; Ince H; Kische S; Schmitz T; Meincke F; Schmidt B; Foley D; Betts TR; Grygier M; Protopopov AV; Stein KM; Boersma LVA
EuroIntervention; 2018 Apr; 13(17):2003-2011. PubMed ID: 29313819
[TBL] [Abstract][Full Text] [Related]
16. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
[TBL] [Abstract][Full Text] [Related]
17. First experience with the Watchman FLX occluder for percutaneous left atrial appendage closure.
Seeger J; Birkemeyer R; Rottbauer W; Wöhrle J
Cardiovasc Revasc Med; 2017; 18(7):512-516. PubMed ID: 28495117
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation: A Single-center, Prospective, Observational Study.
Huang WP; Zhang YH; He L; Su X; Yang XW; Guo ZX
Chin Med J (Engl); 2017 Feb; 130(4):434-438. PubMed ID: 28218217
[TBL] [Abstract][Full Text] [Related]
19. Left Atrial Appendage Occlusion in Patients With Anticoagulation Failure vs Anticoagulation Contraindication.
Aarnink EW; Maarse M; Fierro N; Mazzone P; Beneduce A; Tondo C; Gasperetti A; Pracon R; Demkow M; Zieliński K; de Backer O; Korsholm K; Nielsen-Kudsk JE; Estévez-Loureiro R; Caneiro-Queija B; Benito-González T; Pérez de Prado A; Nombela-Franco L; Salinas P; Holmes D; Almakadma AH; Berti S; Romeo MR; Millan X; Arzamendi D; Alla VM; Agarwal H; Eitel I; Paitazoglou C; Freixa X; Cepas-Guillén P; Chothia R; Badejoko SO; Spoon DB; Maddux JT; El-Chami M; Ram P; Branca L; Adamo M; Suradi HS; Peper J; van Dijk VF; Rensing BJWM; Swaans MJ; Vireca E; Bergmann MW; Boersma LVA;
JACC Cardiovasc Interv; 2024 Jun; 17(11):1311-1321. PubMed ID: 38795093
[TBL] [Abstract][Full Text] [Related]
20. Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low CHA
Lee JM; Kim JB; Uhm JS; Pak HN; Lee MH; Joung B
Heart Rhythm; 2017 Sep; 14(9):1297-1301. PubMed ID: 28559088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
